Endothelium-Derived Vasoactive Substances in Bartter's Syndrome

L. Calò,S. Cantaro,A. Calabró,F. Piarulli,M. Rizzolo,S. Favaro,A. Antonello,Gaetano Crepaldi,A. Borsatti

DOI: https://doi.org/10.1177/000331979504601005

1995-10-01

Angiology

Abstract:An imbalance between endothelium-derived vasoactive substances such as endothelin and endothelium-derived nitric oxide (NO) might be viewed as a possible determinant of vascular hyporeactivity. To check this possibility the authors evaluated the role of endothelin and NO in the reduced vascular reactivity of Bartter's syndrome. Plasma immunoreactive endothelin (22.07 ±7.06 vs 13.80 ±1.43 pmol/L, P < 0.011), urinary excretion of NO 2 - (0.28 ±0.10 vs 0.15 ±0.02, μmol/μmol of urinary creatinine, P < 0.01) and NO3 - (0.17 ±0.07 vs 0.09 ±0.02 μmol/μmol of urinary crea tinine, P < 0.011), and forearm resting blood flow (FRBF) (6.67 ±1.69 vs 4.30 ±0.38 mL/m'/100 mL, P < 0.005) were increased in patients with Bartter's syndrome in comparison with normal controls (C). No difference in postischemic maximal FBF was found (34.14 ±4.67 vs 31.35 ±2.86 mL/minute/100 mL), while patients showed a slower recovery after peak flow (PF) (77.57 ±61.35 vs 9.42 ±3.69 seconds, P < 0.013). Higher plasma endothelin supports the defect in vascular reactivity of Bartter's syndrome already shown for angiotensin II and norepinephrine and is in keeping with the altered intracellular calcium signaling previously demonstrated by the authors in this syndrome. The increased excretion of NO2 - and NO3 - in this syndrome, together with the higher FRBF and the slower recovery of the FBF after PF, argues in favor of an increased NO synthesis in Bartter's syndrome and of assigning it a role in the vascular hyporeactivity of Bartter's syndrome.